Skip to main content
SpringerLink
Log in

Thrombolysis

An Approach Still on the Move

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 25: 4033–4040, 1986

    Article  PubMed  CAS  Google Scholar 

  • Blasko G, Berentey E, Harsanyi A, Sas G. Intracoronarily administered prostacyclin and streptokinase for treatment of myocardial infarction. Advances in Prostaglandin Thromboxane Leukotriene Research 11: 385–390, 1983

    CAS  Google Scholar 

  • Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 229: 765–767, 1985

    Article  PubMed  CAS  Google Scholar 

  • Cambier P, Van de Werf F, Larsen GR, Collen D. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. Journal of Cardiovascular Pharmacology 11: 468–472, 1988

    Article  PubMed  CAS  Google Scholar 

  • Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 74: 583–587, 1986

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 76: 142–154, 1987

    Article  PubMed  CAS  Google Scholar 

  • Collen D, Stassen JM, Stump DC, Verstraete M. In vivo synergism of thrombolytic agents. Circulation 74: 838–842, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Collen D, Stump DC, Van de Werf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. American Heart Journal 112: 1083–1084, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Collen D, Van de Werf F. Coronary thrombolysis with low dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) in man. American Journal of Cardiology 60: 431–444, 1987

    Article  PubMed  CAS  Google Scholar 

  • Coller BS, Folts JD, Scudder LE, Smith SR. Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68: 783–786, 1986

    PubMed  CAS  Google Scholar 

  • Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks binding of fibrinogen to platelets, produces a thromboasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. Journal of Clinical Investigation 12: 325–338, 1983

    Article  Google Scholar 

  • DeWood MA, Spores J, Notske R, Mousser LT, Burroughs R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New England Journal of Medicine 303: 897–902, 1980

    Article  PubMed  CAS  Google Scholar 

  • European Cooperative Study Group. Streptokinase in acute myocardial infarction. New England Journal of Medicine 301: 797–802, 1979

    Article  Google Scholar 

  • Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, et al. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72: 1346–1354, 1985

    Article  PubMed  CAS  Google Scholar 

  • Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, et al. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Journal of the American College of Cardiology 9: 599–607, 1987

    Article  PubMed  CAS  Google Scholar 

  • Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, et al. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thrombosis Research 50: 121–133, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gheysen D, Lijnen HR, Piérard L, de Foresta F, Demarsin E, et al. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator (t-PA) with a truncated single-chain urokinase-type plasminogen activator. Journal of Biological Chemistry 262: 11779–11784, 1987

    PubMed  CAS  Google Scholar 

  • Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77: 670–677, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73: 347–352, 1986

    Article  PubMed  CAS  Google Scholar 

  • Haber E, Runge M, Bode C, Branscomb B, Schnee J, et al. Antibody targeted fibrinolysis. Abstract 924. Thrombosis and Haemostasis 58: 253, 1987

    Google Scholar 

  • ISIS-2. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Second International Study of Infarct Survival Collaborative Group. Lancet 2: 349–360, 1988

    Google Scholar 

  • Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, et al. Coronary thrombolysis in man with pro-urokinase improved efficiency with low dose urokinase. Klinische Wochenschrift 66: 109–114, 1988

    PubMed  Google Scholar 

  • Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 2: 133–142, 1988

    CAS  Google Scholar 

  • Larsen GR, Metzger M, Blue Y, Henderson K. Pharmacokinetics of genetically modified t-PA in the rat. Abstract 1815. Thrombosis and Haemostasis 57: 491, 1987

    Google Scholar 

  • Lau D, Kuzma G, Wei CM, Livingston DJ, Hsiung N. A modified human tissue plasminogen activator with extended half-live in vivo. Biotechnology 5: 953–958, 1987

    Article  CAS  Google Scholar 

  • Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D. Characterization of a chimaeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of urokinase-type plasminogen activator. Journal of Biological Chemistry (in press), 1988

  • Mueller HS, Rao AK, Forman SA, TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. Journal of the American College of Cardiology 10: 479–490, 1987

    Article  PubMed  CAS  Google Scholar 

  • Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombihant human single-chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. Journal of Biological Chemistry 262: 5682–5689, 1987a

    PubMed  CAS  Google Scholar 

  • Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. Journal of Biological Chemistry 262: 10855–10862, 1987b

    PubMed  CAS  Google Scholar 

  • Pâques EP, Stöhr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thrombosis Research 42: 797–807, 1986

    Article  PubMed  Google Scholar 

  • Piérard L, Jacobs P, Gheysen D, Hoylaerts M, André B, et al. Mutant and chimeric recombinant plasminogen activators: production of eukaryotic cells and preliminary characterization. Journal of Biological Chemistry 262: 11771–11778, 1987

    PubMed  Google Scholar 

  • Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, et al. for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Journal of the American College of Cardiology 11: 1–11, 1988

    CAS  Google Scholar 

  • Raynaud P, Desveaux B. Réocclusion après traitement par l’Actilyse. Archives des Maladies du Coeur et des Vaisseaux 81: 25–32, 1988

    PubMed  Google Scholar 

  • Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clinical Cardiology 2: 92–105, 1979

    PubMed  CAS  Google Scholar 

  • Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proceedings of the National Academy of Sciences of the USA (Washington) 84: 7659–7662, 1987

    Article  CAS  Google Scholar 

  • Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proceedings of the National Academy of Sciences of the USA (Washington) 84: 6904–6908, 1987

    Article  CAS  Google Scholar 

  • Sharma B, Wyeth RP, Gimenez HJ, Franciosa JA. Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. American Journal of Cardiology 58: 1161–1166, 1986

    Article  PubMed  CAS  Google Scholar 

  • Simoons ML, Arnold AER, Betriu A, de Bono DP, Col J, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1: 197–202, 1988

    Article  PubMed  CAS  Google Scholar 

  • Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 290: 505–508, 1981

    Article  PubMed  CAS  Google Scholar 

  • Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, et al. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model. Thrombosis and Haemostasis, in press, 1989

  • Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single chain urokinase-type plasminogen activator. Journal of Biological Chemistry 261: 17120–17126, 1986

    PubMed  CAS  Google Scholar 

  • Stürzebecher J, Richter M, Markwardt F. Stable acyl-derivatives of tissue-type plasminogen activator. Thrombosis Research 47: 699–703, 1987

    Article  PubMed  Google Scholar 

  • TIMI Operations Committee, Braunwald E, Knatterud GL, Passamani ER, Robertson TL. Announcement of protocol change in thrombolysis in myocardial infarction. Correspondence. Journal of the American College of Cardiology 9: 467, 1987

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Bates ER, Walton Jr JA, Baumann G, Wolfe S, et al. Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. Journal of the American College of Cardiology 10: 1173–1177, 1987

    Article  PubMed  CAS  Google Scholar 

  • Uchida Y, Hanai T, Hasegawa K, Kawamura K, Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Advances in Prostaglandin Thromboxane Leukotriene Research 11: 377–383, 1983

    CAS  Google Scholar 

  • Van de Werf F, Arnold AER, the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator (rt-PA). Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction. British Medical Journal 297: 1374–1379, 1988

    Article  PubMed  Google Scholar 

  • Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Annals of Internal Medicine 104: 345–348, 1986a

    PubMed  Google Scholar 

  • Van de Werf F, Vanhaecke J, De Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74: 1066–1070, 1986b

    Article  PubMed  Google Scholar 

  • Verstraete M. Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. European Heart Journal 6: 586–593, 1985

    PubMed  CAS  Google Scholar 

  • Verstraete M. The search for the ideal thrombolytic agent. Journal of the American College of Cardiology 10: 4B–10B, 1987

    Article  PubMed  CAS  Google Scholar 

  • Verstraete M. Thrombolysis after myocardial infarction. Erratum. Lancet 1: 763, 1064,1988

    Article  CAS  Google Scholar 

  • Verstraete M, Arnold AER, Brower RW, Collen D, de Bono DP, et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. American Journal of Cardiology 60: 231–237, 1987

    Article  PubMed  CAS  Google Scholar 

  • Verstraete M, Bernard R, Bory M, Brower RW, Collen D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1: 842–847, 1985

    Article  PubMed  CAS  Google Scholar 

  • Verstraete M, van de Loo J, Jesdinsky HJ (Eds). Streptokinase in acute myocardial infarction. Acta Medica Scandinavica Supplementum 648, 1981

  • Welzel D, Wolf H. Clinical research on single-chain urokinase-type plasminogen activator (scu-PA) in Germany: results in patients with acute myocardial infarction (AMI). Abstract 160. Thrombosis and Haemostasis 58: 47, 1987

    Google Scholar 

  • Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. European Heart Journal 6: 556–585, 1985

    PubMed  CAS  Google Scholar 

  • Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, et al. Coronary thrombolysis in dogs with synergistic combinations of human tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA). Clinical Research 35: 337A, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Thrombosis and Vascular Research, University of Leuven, Campus Gasthuisberg, Building Teaching and Research, Herestraat 49, B-3000, Leuven, Belgium

    Marc Verstraete

Authors
  1. Marc Verstraete
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verstraete, M. Thrombolysis. Drugs 37, 116–122 (1989). https://doi.org/10.2165/00003495-198937020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198937020-00002

Keywords

Search

Navigation